InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Next-Generation Sequencing in Drug Discovery Market Size, Share & Trends Analysis Report Product Type (Instruments, Consumables, and Software & Services) By Technology (Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, Chip-Sequencing (ChIP-Seq), and De Novo Sequencing) By Application (Drug Target Identification, Pharmacogenomics, Toxicogenomic, and Clinical Trial Stratification) By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Hospitals & Clinics) By Workflow (Sample Preparation, Sequencing, Data Analysis, and Data Interpretation)-Market Outlook And Industry Analysis 2034″
Next-Generation Sequencing in Drug Discovery Market Size is valued at US$ 1.3 Bn in 2024 and is predicted to reach US$ 7.5 Bn by the year 2034 at an 19.7% CAGR during the forecast period for 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3176
Next-generation sequencing in drug discovery is a high-throughput DNA sequencing technology applied to the rapid examination of genetic differences, the discovery of drug targets, and the elucidation of disease mechanisms to facilitate the development of targeted and effective therapeutics.
Increasing use in precision medicine and targeted therapies propels market expansion. NGS facilitates rapid, high-throughput analysis of genomes that helps identify disease-causing mutations and biomarkers. It speeds up drug development, saves money, and maximizes the effectiveness of treatment, hence becoming an important instrument for drug manufacturers to develop tailored therapeutics.
The expanding use of next-generation sequencing in drug discovery is fueled by its capacity to provide high-throughput, accurate genetic information, facilitating the acceleration of target discovery and biomarker identification. Its scalability and cost-effectiveness enable rapid candidate screening of drugs.
Its expanding application in rare disease research is a major driver, as next-generation sequencing allows for the detection of rare genetic variants, leading the way to personalized therapy. This expands drug development pipelines and optimizes treatment outcomes for previously incurable diseases.
List of Prominent Players in the Next-Generation Sequencing in Drug Discovery Market:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Hoffmann-La Roche Ltd. (Roche)
- QIAGEN N.V
- BGI Genomics Co., Ltd.
- Bio-Rad Laboratories, Inc.
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California, Inc. (PacBio)
- PerkinElmer, Inc.
- Genapsys, Inc.
- Eurofins Scientific
- Macrogen, Inc.
- Takara Bio Inc.
- DNAnexus, Inc.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics:
Drivers-
The next-generation sequencing in the drug discovery market is growing strongly, driven by increased investment in biopharmaceutical R&D. The pharmaceutical and biotechnology industries are investing heavily in advanced genomic technologies to accelerate drug discovery and development. NGS provides high-throughput sequencing of genetic material, enabling researchers to map disease-causing mutations, uncover new targets for drugs, and tailor treatments to individuals.
The accuracy and throughput of NGS are revolutionizing preclinical and clinical research operations, saving time-to-market and development costs. Additionally, public and private funding of precision medicine programs and genomic research is driving innovation, making NGS a foundational technology in the future of drug development.
Challenges:
A key restraint in the next-generation sequencing in the drug discovery market is limited access in low-resource settings. Although revolutionizing potential, NGS technology is still largely out of reach in most developing countries owing to expense, the absence of infrastructure, and a shortage of skilled experts. Setting up and sustaining NGS platforms demands significant investment in hardware, reagents, and computational software, which may be cost-prohibitive for low-income healthcare and research facilities.
In addition, poor internet connectivity and limited bioinformatics capacity impede data analysis and interpretation. This hinders adoption on a large scale, limiting the global reach of NGS-aided drug discovery, especially in regions where new therapies for infectious diseases and genetic diseases are urgently required.
Regional Trends:
North America, particularly the United States, has the largest next-generation sequencing in drug discovery market globally. This is due to the escalating demand for precision medicine, expanding R&D spending, and improved genomic technologies. The pharmaceutical and biotech industries are utilizing next-generation sequencing in drug discovery to discover new drug targets, accelerate biomarker discovery, and optimize clinical trial design.
Government incentives, including NIH grants and regulatory ease in conducting genomics research, also provide additional impetus to market growth. A strong healthcare infrastructure in the region and the presence of major industry stakeholders are responsible for the broad-based adoption of NGS in early-stage drug development.
In addition, Europe’s next-generation sequencing in drug discovery market is driven by advances in genomic research and rising demand for personalized medicine. NGS facilitates high-throughput analysis of genetic variation, enabling pharmaceutical market players to identify new drug targets and biomarkers more accurately.
Genomics-supportive initiatives like Horizon Europe and national genome projects are also promoting R&D investments in Europe. Also, the robust biopharma industry within the region, combined with the partnerships between universities and biotechnology companies, drives the adoption of NGS technologies into early drug discovery processes.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3176
Recent Developments:
- February 2025: Roche launched its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new segment of next-generation sequencing. SBX chemistry, along with a creative sensor module, provides ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications.
- April 2024: Bio-Rad Laboratories, Inc. Incannounced a collaboration agreement with Oncocyte Corporation, a precision diagnostics firm, to develop and commercialize transplant monitoring products utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) instruments and reagents.
Segmentation of Next-Generation Sequencing in Drug Discovery Market-
By Product Type-
- Instruments
- Consumables
- Software & Services
By Technology –
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Targeted Sequencing
- Chip-Sequencing (ChIP-Seq)
- De Novo Sequencing
By Application-
- Drug Target Identification
- Pharmacogenomics
- Toxicogenomic
- Clinical Trial Stratification
By End-user-
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Hospitals & Clinics
By Workflow-
- Sample Preparation
- Sequencing
- Data Analysis
- Data Interpretation
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
